Seeking Alpha

GlaxoSmithKline's (GSK) Votrient, which is approved to treat kidney cancer or soft-tissue...

GlaxoSmithKline's (GSK) Votrient, which is approved to treat kidney cancer or soft-tissue sarcoma, extended the time taken for ovarian cancer to worsen in patients by an average of 5.6 months in a Phase III trial. The results suggest that Votrient could be used as a "maintenance" therapy, although an interim analysis found no difference in overall survival rates between the drug and a placebo. The findings were presented at the annual meeting of the American Society of Clinical Oncology. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|